01763 CIRC
- 11.080
- 0.0000.00%
CIRC News
CIRC To Go Ex-Dividend On June 19th, 2024 With 0.34521 HKD Dividend Per Share
May 8th - $CIRC(01763.HK)$ is trading ex-dividend on June 19th, 2024. Shareholders of record on June 20th, 2024 will receive 0.34521 HKD dividend per share on August 13th, 2024. The ex-dividend da
China Tongshi (01763) will pay a final dividend of 0.3131 yuan per share on August 13
China Tongshi (01763) announced that the company will pay a final dividend of 0 per share on August 13, 2024...
Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
China Tongfu announced on the Hong Kong Stock Exchange on the evening of May 6 that Xu Hongchao's resignation as an executive director of the company, a member of the board's strategy committee, and a member of the Science and Technology Innovation Commit
China Tongfu announced on the Hong Kong Stock Exchange on the evening of May 6 that Xu Hongchao's resignation as an executive director of the company, a member of the board's strategy committee, and a member of the Science and Technology Innovation Committee took effect when the company's shareholders approved the appointment of Wang Yao as the company's executive director at the shareholders' meeting. Xu Hongchao also resigned as general manager of the company due to job adjustments effective May 6, 2024.
China Tongfu (01763.HK) appoints Wang Yao as the company's general manager
Gelonghui, May 6, 丨 China Tongpo (01763.HK) announced that Mr. Xu Hongchao resigned as an executive director of the company, a member of the Board's Strategy Committee, and a member of the Science and Technology Innovation Committee due to job adjustments. The shareholders of the company approved the appointment of Mr. Wang Yao as the company's executive director at the shareholders' meeting. Mr. Xu Hongchao also resigned as general manager of the company due to job adjustments, effective May 6, 2024. On May 6, 2024, the board of directors resolved to appoint Mr. Wang Yao as the executive director of the fourth board of directors. The term of office starts from the date of review and approval by the company's shareholders' meeting until the end of the fourth board of directors
Hong Kong Stock Concept Tracking | China's Nuclear Medicine Industry Attracts Attention (with concept stocks), the key technology for batch online irradiation production of isotopes
Various short-half-life medical isotopes that are currently in short supply in China will enter the large-scale production stage after the supporting plant is completed and put into operation in the second half of this year.
中國同輻：2023年度報告
Changes in Hong Kong stocks | China Tongshi (01763) rose more than 4%, China Nuclear Qualcomm officially has the capacity to produce and supply Nuclides such as Wancuri GMP grade N-177
The Zhitong Finance App learned that China's Tongbo (01763) rose by more than 4%. As of press release, it had risen 3.85% to HK$10.26, with a turnover of HK$1,228,800. According to the news, the China Communications Agency announced that recently, the first domestic production line with an annual output of Wanjuli grade Carrier-free Zi-177 GMP and an annual production capacity of 1,000 germanium 68Ge-68Ga generators was fully completed and put into operation, marking the actual realization of large-scale commercialization of the two GMP-grade GMP-grade GE-177 and Gallium-68 medical nuclides. The smooth commissioning of the production line will effectively mitigate domestic supply shortages of Zn-177 and Gallium-68
China Tongfu announced on the Hong Kong Stock Exchange recently that the first domestic production line with an annual output of 10,000 Juri—grade carrier-free GM—177GMP production line, with an annual production capacity of 1,000-grade germanium and gall
China Tongfu announced on the Hong Kong Stock Exchange recently that the first domestic production line with an annual output of 10,000 Juri—grade carrier-free GM—177GMP production line, with an annual production capacity of 1,000-grade germanium and gallium-68Ga, has been fully completed and put into operation, marking the actual realization of large-scale commercialization of the two types of GMP grade -177 and gallium-68 medical nuclides. The smooth commissioning of the production line will effectively mitigate the problem of insufficient domestic supply of Zn-177 and Gallium-68, which is heavily dependent on imports.
China Tongshi (01763.HK): CNNC Qualcomm officially has the capacity to produce and supply Nuclides such as Wancuri GMP grade -177
Gelonghui, April 22 | China Tongzhu (01763.HK) announced that recently, the first domestic-produced Wanjuli grade carrier-free -177 GMP production line, with an annual production capacity of 1,000 germanium gallium 68Ge-68Ga generators, has been fully completed and put into operation, marking the actual realization of the large-scale commercial supply of GMP-grade GMP-grade GE-177 and Gallium-68 medical nuclides.
Changes in Hong Kong stocks | China Tongshi (01763) rose more than 7% intraday to achieve full localization of carbon-14 isotopes supply
China Tongshi (01763) rose more than 7% in the intraday period. As of press release, it rose 6.49% to HK$9.85, with a turnover of HK$3.564,400.
Hong Kong Stock Concept Tracking | China's first mass production of carbon-14 isotope domestically produced nuclear drugs ushered in new opportunities (with concept stocks)
At 13:48 on April 20, after two years of core irradiation, the first carbon-14 target was successfully removed from the Qinshan Nuclear Power Heavy Water Reactor Unit of China Nuclear Power Investment Holdings under the China Nuclear Power Group. This was the first time that China mass-produced carbon-14 isotopes, solving the problem that domestic carbon-14 isotopes are dependent on imports, and fully localizing carbon-14 supply. Carbon-14 is a radioactive isotope of carbon and is widely used as a tracer. Helicobacter pylori testing is its most representative use. In addition, fields such as pharmacokinetic research and beta-ray environmental monitoring systems also require carbon-14. Previously
Tongfu, China: Economic benefits will continue to grow in 2023, annual revenue of 6.635 billion yuan
Gelonghui, April 17 | China Tongpo (1763.HK) announced that in 2023, the company will continue to increase its market development efforts and achieve continuous growth in economic efficiency. The full year achieved operating income of RMB 6.635 billion, up 7.82% year on year; net profit of RMB 776 million, up 2.77% year on year; and net profit to mother of RMB 371 million. Earnings per share were RMB 1.16. The company operates five business divisions: pharmaceuticals, radiogenic products, radiation therapy equipment and related services, as well as other business divisions. The development of the pharmaceutical business stock industry is in full swing, through academic conferences, etc.
Express News | Yinlong Co., Ltd. and China Tongfu set up sterilization technology companies
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Innovative drugs continue to warm up! Joint policies in many places catalyze the strengthening of the pharmaceutical sector in Hong Kong stocks
Recently, support policies for the innovative pharmaceutical industry have been issued in many places, bringing a new market catalyst to the currently relatively deserted pharmaceutical stocks. The Hong Kong stock pharmaceutical sector is also active today.
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
China Isotope & Radiation to Form JV Company
China Isotope & Radiation (HKG:1763) has entered into an agreement to form a joint venture company with CNNC Hainan Nuclear Power, a Wednesday filing on the Hong Kong bourse by the radiopharmaceutical
China Tongpo (01763.HK) plans to establish a joint venture to carry out deep processing services such as preservation, preservation and sterilization of specialty agricultural products
Gelonghui, April 3, 丨 China Tongpu (01763.HK) announced that on April 3, 2024, the company and CNNC Hainan Nuclear Power entered into an investment cooperation agreement to establish a joint venture. According to the investment cooperation agreement, the registered capital of the joint venture is RMB 50 million, of which the company will invest RMB 25.5 million in monetary capital, and CNNC Hainan Nuclear Power will invest RMB 24.5 million in monetary capital. After the establishment of the joint venture, the company and CNNC Hainan Nuclear Power will hold 51% and 49% of the shares in the joint venture, respectively, and the joint venture will become a subsidiary of the company. The joint venture will use an electron accelerator
Analysis
Price Target
No Data
